525O A phase I dose escalation study of PRS-343, a HER2/4-1BB bispecific molecule, in patients with HER2-positive malignancies

Geoffrey Y. Ku, J.C. Bendell, A. W. Tolcher, Sara A. Hurvitz, Anuradha Krishnamurthy, Anthony B. El-Khoueiry, Amita Patnaik, Rachna T. Shroff, Anne M. Noonan, Noah M. Hahn, Marc Matrana, Markus Zettl, Kayti Aviano, Lynn Mar, Patrick Jolicoeur, Shane A. Olwill, Ingmar Bruns, Sarina A. Piha‐Paul